SpringWorks Therapeutics, Inc.
BioSniper Score
4-factor signal
Market Cap
—
Cash Runway
6.6 mo
Lead Asset
bgb-3245 (Phase 1/Phase 2)
Next Catalyst
—
SpringWorks Therapeutics, Inc.: 11 pipeline candidates · 12 clinical trials · 1 FDA decision · Updated within the last hour.
Go deeper on SpringWorks Therapeutics, Inc. with Spotter
Ask follow-up questions and run a full multi-agent deep dive on SWTX — live, with citations.
Score breakdown4-factor signal · derived from public data
6.6 months
D/E 0.21 · 0% dilution
Lead: Phase 3
11 candidates
N/A
N/A
Key Financialsas of March 31, 2025
Cash
$64.4M
Quarterly Burn
$68.8M
Revenue
$49.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| bgb-3245 | Phase 1/Phase 2 |
| brimarafenib | Phase 1/Phase 2 |
| combination therapy | Phase 1/Phase 2 |
| gomekli | Phase 2 |
| mirdametinib | Phase 2 |
| mirdametinib | Phase 2 |
| mirdametinib | Phase 2 |
| nirogacestat | Phase 3 |
| ogsiveo | Phase 4 |
| sw-3431 | Preclinical |
Showing 10 of 11 candidates. Sign up for full pipeline.
Frequently asked questions
What is SpringWorks Therapeutics, Inc.'s lead drug candidate?
SpringWorks Therapeutics, Inc.'s most advanced tracked candidate is bgb-3245 (Phase 1/Phase 2) for Advanced Solid Tumor.
Who is the CEO of SpringWorks Therapeutics, Inc.?
Saqib Islam Saqib is the chief executive officer of SpringWorks Therapeutics, Inc. (SWTX).
What therapeutic areas does SpringWorks Therapeutics, Inc. focus on?
SpringWorks Therapeutics, Inc. develops therapies across Oncology, Rare Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on SpringWorks Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.